Navigation Links
2013 Gastrointestinal Cancers Symposium reveals new advances for GI cancers
Date:1/22/2013

ALEXANDRIA, Va. New research into the treatment and prognosis of gastrointestinal cancers was released today in advance of the tenth annual Gastrointestinal Cancers Symposium being held January 24-26, 2013, at The Moscone West Building in San Francisco, CA.

Five important studies were highlighted today in a live presscast:

  • Postoperative Treatment with S-1 Chemotherapy Reduces Relapses and Extends Survival in Patients with Pancreatic Cancer: Early results from a Phase III clinical trial conducted in Japan show patients who received the chemotherapy drug S-1 after surgery for Stage I-III pancreatic adenocarcinoma had a 44 percent lower risk of dying compared with patients treated with gemcitabine. While S-1 is not yet approved in the United States, it is available in several Asian and European countries.

  • New Molecular Classification System for Colorectal Cancer May Help Guide Treatment Choice for Individual Patients: Researchers identified three distinct colorectal cancer subtypes based on gene expression patterns in patients' tumors. The findings may lead to new molecular tests for determining if a patient needs adjuvant treatment and which treatment might be most beneficial.

  • Surgery Following Imatinib Therapy Substantially Improves Survival for Certain Patients with Gastrointestinal Stromal Tumors (GISTs): A new retrospective study validated the benefit of performing surgery to remove residual tumor lesions after imatinib therapy. Patients who received surgery after imatinib had a 5.5 fold lower risk of dying and a nearly 4-year longer time to disease worsening compared with those who received imatinib alone.

  • Profiling Gene Expression in Circulating Tumor Cells Shows Promise as a New Prognostic Strategy for Patients with Pancreatic Cancer: A study profiling gene expression in cells shed from pancreatic tumors into the bloodstream detected genomic changes associated with response and resistance to different treatments. This new profiling strategy may help predict whether or not a patient would respond to a particular chemotherapy regimen.

  • Second-Line Docetaxel Chemotherapy Improves Survival in Patients with Treatment-Resistant Esophageal or Gastric Cancers: A Phase III study showed that patients with esophageal or stomach cancers whose disease worsened despite first-line chemotherapy live on average 50 percent longer if they received second-line docetaxel than if they receive active symptom control (radiotherapy, steroids, and/or supportive medications). While docetaxel is already being used in this setting, the new study provides definitive evidence of survival benefit with second-line docetaxel.

"Research continues to deliver advances that will improve the lives of patients with gastrointestinal cancers, and we are learning to understand how to use molecular characteristics of tumors to choose and customize therapy for individual patients," said Neal J. Meropol, MD, who moderated the presscast. "At this conference, we will see the results of new studies showing life-extending treatments for some of our deadliest and hardest to treat cancers and new insights on tumor classification and prognosis."

Gastrointestinal cancers include those of the colon/rectum, stomach, pancreas, esophagus, small intestine, anus and other digestive organs. In 2012, it was estimated that nearly 285,000 people in the U.S. were diagnosed with these cancers and more than 142,000 will died from them.


'/>"/>

Contact: Susie Tappouni
susie.tappouni@asco.org
571-483-1355
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
2. Gastroenterology Societies issue sedation curriculum for gastrointestinal endoscopy
3. Dietary fiber alters gut bacteria, supports gastrointestinal health
4. New analysis of drinking water-related gastrointestinal illness
5. Study Assesses Blood Thinner Use After Gastrointestinal Bleeding
6. Targeting neurotransmitter may help treat gastrointestinal conditions
7. Which Hospital Patients Need Drugs to Prevent Gastrointestinal Bleeding?
8. Potential new treatment for gastrointestinal cancers discovered
9. HPV-Related Head, Neck Cancers on the Rise
10. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
11. Kinase test may yield big gains for drug-resistant cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider ... Online(TM), which enables sleep physicians to create and edit their interpretation reports. This ... provides a familiar interface that does not require additional training to use. It ...
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... ... Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven one- ...
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology: